Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
HPV-Negative Squamous Cell Carcinoma
DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Cetuximab|RADIATION: Standard Dose Radiation|RADIATION: Low Dose Radiation|DRUG: Cisplatin|DRUG: TFHX Regimen
Percentage of participants that complete study treatment and provide all required research blood draws., To be measured at end of treatment period (9 weeks)|Determine if ctDNA levels is predicative of disease response, Researchers will look at amount of ctDNA in the blood to determine if it correlates to disease response based on imaging results per RECIST v1.1., To be measured at end of treatment period (9 weeks)
Number of participants with side effects related to study treatment, To be measured at 3 months after end of treatment period|Long Term Disease Response based on RECIST 1.1, To be assessed at 2 years after end of treatment period
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.